Warner Greene, MD, PhD

Bio

Honors and Awards

Publications

• Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Gascon R, Tsou CL, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Morris MK, Wadford D, Hanson C, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna JA, Ott M. Nature. 2022 May 18.
• Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. Matsui Y, Li L, Prahl M, Cassidy AG, Ozarslan N, Golan Y, Gonzalez VJ, Lin CY, Jigmeddagva U, Chidboy MA, Montano M, Taha TY, Khalid MM, Sreekumar B, Hayashi JM, Chen PY, Kumar GR, Warrier L, Wu AH, Song D, Jegatheesan P, Rai DS, Govindaswami B, Needens JM, Rincon M, Myatt L, Asiodu IV, Flaherman VJ, Afshar Y, Jacoby VL, Murtha AP, Robinson JF, Ott M, Greene WC, Gaw SL. JCI Insight. 2022 May 17.
• Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination. Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna J, Ott M. medRxiv. 2022 Feb 09.
• Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. George AF, Luo X, Neidleman J, Hoh R, Vohra P, Thomas R, Shin MG, Lee MJ, Blish CA, Deeks SG, Greene WC, Lee SA, Roan NR. Front Immunol. 2022; 13:803417.
• Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and early infancy. Prahl M, Golan Y, Cassidy AG, Matsui Y, Li L, Alvarenga B, Chen H, Jigmeddagva U, Lin CY, Gonzalez VJ, Chidboy MA, Warrier L, Buarpung S, Murtha AP, Flaherman VJ, Greene WC, Wu AHB, Lynch KL, Rajan J, Gaw SL. medRxiv. 2021 Dec 13.
• Cell-Extrinsic Priming Increases Permissiveness of CD4+ T Cells to Human Immunodeficiency Virus Infection by Increasing C-C Chemokine Receptor Type 5 Co-receptor Expression and Cellular Activation Status. Pedersen JG, Egedal JH, Packard TA, Thavachelvam K, Xie G, van der Sluis RM, Greene WC, Roan NR, Jakobsen MR. Front Microbiol. 2021; 12:763030.
• SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. Ryu JK, Sozmen EG, Dixit K, Montano M, Matsui Y, Liu Y, Helmy E, Deerinck TJ, Yan Z, Schuck R, Acevedo RM, Spencer CM, Thomas R, Pico AR, Zamvil SS, Lynch KL, Ellisman MH, Greene WC, Akassoglou K. bioRxiv. 2021 Oct 13.
• mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR. Elife. 2021 10 12; 10.
• Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission. Luo X, Mouquet H, Schwartz O, Greene WC. J Biol Chem. 2021 10; 297(4):101098.
• mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR. bioRxiv. 2021 Jul 29.
• Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, Murray V, Gill G, Greene WC, Vasquez J, Lee SA, Ghosn E, Lynch KL, Roan NR. Cell Rep. 2021 07 20; 36(3):109414.
• Hyaluronic acid is a negative regulator of mucosal fibroblast-mediated enhancement of HIV infection. Egedal JH, Xie G, Packard TA, Laustsen A, Neidleman J, Georgiou K, Pillai SK, Greene WC, Jakobsen MR, Roan NR. Mucosal Immunol. 2021 09; 14(5):1203-1213.
• Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. Xie G, Luo X, Ma T, Frouard J, Neidleman J, Hoh R, Deeks SG, Greene WC, Roan NR. Cell Rep. 2021 04 27; 35(4):109038.
• Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, Murray V, Gill G, Greene WC, Vasquez J, Lee S, Ghosn E, Lynch K, Roan NR. medRxiv. 2021 Feb 05.
• Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo. Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, Sperber HS, Hull PA, Montano M, Migueles SA, Rosenthal D, Hogan LE, Johnson JR, Packard TA, Grimmett ZW, Herzig E, Besnard E, Nekorchuk M, Hsiao F, Deeks SG, Snape M, Kiernan B, Roan NR, Lifson JD, Estes JD, Picker LJ, Verdin E, Krogan NJ, Henrich TJ, Connors M, Ott M, Pillai SK, Okoye AA, Greene WC. J Virol. 2021 Feb 03.
• Identification of unrecognized host factors promoting HIV-1 latency. Li Z, Hajian C, Greene WC. PLoS Pathog. 2020 12; 16(12):e1009055.
• Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+ T cells from ART-treated individuals. Moron-Lopez S, Telwatte S, Sarabia I, Battivelli E, Montano M, Macedo AB, Aran D, Butte AJ, Jones RB, Bosque A, Verdin E, Greene WC, Wong JK, Yukl SA. PLoS Pathog. 2020 11; 16(11):e1009060.
• Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. Neidleman J, Luo X, Frouard J, Xie G, Hsiao F, Ma T, Morcilla V, Lee A, Telwatte S, Thomas R, Tamaki W, Wheeler B, Hoh R, Somsouk M, Vohra P, Milush J, James KS, Archin NM, Hunt PW, Deeks SG, Yukl SA, Palmer S, Greene WC, Roan NR. Elife. 2020 09 29; 9.
• SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, McGregor M, Ma T, George AF, Kosters A, Greene WC, Vasquez J, Ghosn E, Lee S, Roan NR. Cell Rep Med. 2020 09 22; 1(6):100081.
• SARS-CoV-2-specific T cells exhibit unique features reflecting robust helper function, lack of terminal differentiation, and high proliferative potential. Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, McGregor M, Ma T, George A, Kosters A, Greene WC, Vasquez J, Ghosn E, Lee S, Roan NR. bioRxiv. 2020 Aug 03.
• HIV efficiently infects T cells from the endometrium and remodels them to promote systemic viral spread. Ma T, Luo X, George AF, Mukherjee G, Sen N, Spitzer TL, Giudice LC, Greene WC, Roan NR. Elife. 2020 05 26; 9.
• Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. Hsiao F, Frouard J, Gramatica A, Xie G, Telwatte S, Lee GQ, Roychoudhury P, Schwarzer R, Luo X, Yukl SA, Lee S, Hoh R, Deeks SG, Jones RB, Cavrois M, Greene WC, Roan NR. PLoS Pathog. 2020 04; 16(4):e1008450.
• Seminal plasma promotes decidualization of endometrial stromal fibroblasts in vitro from women with and without inflammatory disorders in a manner dependent on interleukin-11 signaling. George AF, Jang KS, Nyegaard M, Neidleman J, Spitzer TL, Xie G, Chen JC, Herzig E, Laustsen A, Marques de Menezes EG, Houshdaran S, Pilcher CD, Norris PJ, Jakobsen MR, Greene WC, Giudice LC, Roan NR. Hum Reprod. 2020 03 27; 35(3):617-640.
• Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy. Schwarzer R, Gramatica A, Greene WC. Viruses. 2020 02 08; 12(2).
• HIV-2 Depletes CD4 T Cells through Pyroptosis despite Vpx-Dependent Degradation of SAMHD1. Luo X, Herzig E, Doitsh G, Grimmett ZW, Muñoz-Arias I, Greene WC. J Virol. 2019 12 15; 93(24).
• Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency. Telwatte S, Morón-López S, Aran D, Kim P, Hsieh C, Joshi S, Montano M, Greene WC, Butte AJ, Wong JK, Yukl SA. Retrovirology. 2019 11 11; 16(1):32.
• Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform. Herzig E, Kim KC, Packard TA, Vardi N, Schwarzer R, Gramatica A, Deeks SG, Williams SR, Landgraf K, Killeen N, Martin DW, Weinberger LS, Greene WC. Cell. 2019 10 31; 179(4):880-894.e10.
• Tissue microenvironment initiates an immune response to structural components of Staphylococcus aureus. Mainzer C, Packard T, Bordes S, Closs B, Greene WC, Elias PM, Uchida Y. Exp Dermatol. 2019 02; 28(2):161-168.
• Distinct mechanisms regulate IL1B gene transcription in lymphoid CD4 T cells and monocytes. Pulugulla SH, Packard TA, Galloway NLK, Grimmett ZW, Doitsh G, Adamik J, Galson DL, Greene WC, Auron PE. Cytokine. 2018 11; 111:373-381.
• Potent and rapid activation of tropomyosin-receptor kinase A in endometrial stromal fibroblasts by seminal plasma. Martin JW, Chen JC, Neidleman J, Tatsumi K, Hu J, Giudice LC, Greene WC, Roan NR. Biol Reprod. 2018 08 01; 99(2):336-348.
• Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells. Battivelli E, Dahabieh MS, Abdel-Mohsen M, Svensson JP, Tojal Da Silva I, Cohn LB, Gramatica A, Deeks S, Greene WC, Pillai SK, Verdin E. Elife. 2018 05 01; 7.
• Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells. Cavrois M, Banerjee T, Mukherjee G, Raman N, Hussien R, Rodriguez BA, Vasquez J, Spitzer MH, Lazarus NH, Jones JJ, Ochsenbauer C, McCune JM, Butcher EC, Arvin AM, Sen N, Greene WC, Roan NR. Cell Rep. 2017 07 25; 20(4):984-998.
• Semen amyloids participate in spermatozoa selection and clearance. Roan NR, Sandi-Monroy N, Kohgadai N, Usmani SM, Hamil KG, Neidleman J, Montano M, Ständker L, Röcker A, Cavrois M, Rosen J, Marson K, Smith JF, Pilcher CD, Gagsteiger F, Sakk O, O'Rand M, Lishko PV, Kirchhoff F, Münch J, Greene WC. Elife. 2017 06 27; 6.
• SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency. Boehm D, Jeng M, Camus G, Gramatica A, Schwarzer R, Johnson JR, Hull PA, Montano M, Sakane N, Pagans S, Godin R, Deeks SG, Krogan NJ, Greene WC, Ott M. Cell Host Microbe. 2017 May 10; 21(5):569-579.e6.
• Corrigendum: Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Muñoz-Arias I, Greene WC. Nature. 2017 04 06; 544(7648):124.
• Mucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells. Neidleman JA, Chen JC, Kohgadai N, Müller JA, Laustsen A, Thavachelvam K, Jang KS, Stürzel CM, Jones JJ, Ochsenbauer C, Chitre A, Somsouk M, Garcia MM, Smith JF, Greenblatt RM, Münch J, Jakobsen MR, Giudice LC, Greene WC, Roan NR. PLoS Pathog. 2017 02; 13(2):e1006163.
• The mTOR Complex Controls HIV Latency. Besnard E, Hakre S, Kampmann M, Lim HW, Hosmane NN, Martin A, Bassik MC, Verschueren E, Battivelli E, Chan J, Svensson JP, Gramatica A, Conrad RJ, Ott M, Greene WC, Krogan NJ, Siliciano RF, Weissman JS, Verdin E. Cell Host Microbe. 2016 Dec 14; 20(6):785-797.
• Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK. Nat Med. 2016 07; 22(7):807-11.
• Gallic Acid Is an Antagonist of Semen Amyloid Fibrils That Enhance HIV-1 Infection. LoRicco JG, Xu CS, Neidleman J, Bergkvist M, Greene WC, Roan NR, Makhatadze GI. J Biol Chem. 2016 Jul 01; 291(27):14045-14055.
• Dissecting How CD4 T Cells Are Lost During HIV Infection. Doitsh G, Greene WC. Cell Host Microbe. 2016 Mar 09; 19(3):280-91.
• Blood-Derived CD4 T Cells Naturally Resist Pyroptosis during Abortive HIV-1 Infection. Muñoz-Arias I, Doitsh G, Yang Z, Sowinski S, Ruelas D, Greene WC. Cell Host Microbe. 2015 Oct 14; 18(4):463-70.
• Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-Derived CD4 T Cells. Galloway NL, Doitsh G, Monroe KM, Yang Z, Muñoz-Arias I, Levy DN, Greene WC. Cell Rep. 2015 Sep 08; 12(10):1555-1563.
• MicroRNA-155 Reinforces HIV Latency. Ruelas DS, Chan JK, Oh E, Heidersbach AJ, Hebbeler AM, Chavez L, Verdin E, Rape M, Greene WC. J Biol Chem. 2015 May 29; 290(22):13736-48.
• Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides. Zirafi O, Kim KA, Roan NR, Kluge SF, Müller JA, Jiang S, Mayer B, Greene WC, Kirchhoff F, Münch J. Sci Transl Med. 2014 Nov 12; 6(262):262ra157.
• HIV-1 Fusion Assay. Cavrois M, Neidleman J, Greene WC. Bio Protoc. 2014 Aug 20; 4(16).
• A new activity for SAMHD1 in HIV restriction. Yang Z, Greene WC. Nat Med. 2014 Aug; 20(8):808-9.
• Liquefaction of semen generates and later degrades a conserved semenogelin peptide that enhances HIV infection. Roan NR, Liu H, Usmani SM, Neidleman J, Müller JA, Avila-Herrera A, Gawanbacht A, Zirafi O, Chu S, Dong M, Kumar ST, Smith JF, Pollard KS, Fändrich M, Kirchhoff F, Münch J, Witkowska HE, Greene WC. J Virol. 2014 Jul; 88(13):7221-34.
• Interaction of fibronectin with semen amyloids synergistically enhances HIV infection. Roan NR, Chu S, Liu H, Neidleman J, Witkowska HE, Greene WC. J Infect Dis. 2014 Oct 01; 210(7):1062-6.
• Direct visualization of HIV-enhancing endogenous amyloid fibrils in human semen. Usmani SM, Zirafi O, Müller JA, Sandi-Monroy NL, Yadav JK, Meier C, Weil T, Roan NR, Greene WC, Walther P, Nilsson KP, Hammarström P, Wetzel R, Pilcher CD, Gagsteiger F, Fändrich M, Kirchhoff F, Münch J. Nat Commun. 2014 Apr 01; 5:3508.
• Seminal plasma induces global transcriptomic changes associated with cell migration, proliferation and viability in endometrial epithelial cells and stromal fibroblasts. Chen JC, Johnson BA, Erikson DW, Piltonen TT, Barragan F, Chu S, Kohgadai N, Irwin JC, Greene WC, Giudice LC, Roan NR. Hum Reprod. 2014 Jun; 29(6):1255-70.
• Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Muñoz-Arias I, Greene WC. Nature. 2014 Jan 23; 505(7484):509-14.
• An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. PLoS Pathog. 2013; 9(12):e1003834.
• IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, Greene WC. Science. 2014 Jan 24; 343(6169):428-32.
• Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains. Cavrois M, Neidleman J, Santiago ML, Derdeyn CA, Hunter E, Greene WC. J Virol. 2014 Feb; 88(4):2083-94.
• Solutions to global health challenges: no more Band-Aids. Greene WC. J Clin Invest. 2013 Nov; 123(11):4967-70.
• Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV. Chan JK, Bhattacharyya D, Lassen KG, Ruelas D, Greene WC. PLoS One. 2013; 8(10):e77749.
• An integrated overview of HIV-1 latency. Ruelas DS, Greene WC. Cell. 2013 Oct 24; 155(3):519-29.
• Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. Webster B, Ott M, Greene WC. J Virol. 2013 Dec; 87(24):13354-69.
• Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein. Vogt DA, Camus G, Herker E, Webster BR, Tsou CL, Greene WC, Yen TS, Ott M. PLoS Pathog. 2013; 9(4):e1003302.
• Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. Webster B, Wissing S, Herker E, Ott M, Greene WC. J Virol. 2013 Jan; 87(1):581-96.
• [Role of semen-derived amyloid fibrils as facilitators of HIV infection]. Roan NR, Cavrois M, Greene WC. Med Sci (Paris). 2012 Apr; 28(4):358-60.
• Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis. Chan JK, Greene WC. Immunol Rev. 2012 Mar; 246(1):286-310.
• Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong JK, Swiss HIV Cohort Study. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):3035-40.
• A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC. PLoS One. 2012; 7(1):e30176.
• Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, Levy JA, Palefsky JM. J Virol. 2012 Mar; 86(5):2556-70.
• Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Roan NR, Müller JA, Liu H, Chu S, Arnold F, Stürzel CM, Walther P, Dong M, Witkowska HE, Kirchhoff F, Münch J, Greene WC. Cell Host Microbe. 2011 Dec 15; 10(6):541-50.
• Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. Arnold F, Schnell J, Zirafi O, Stürzel C, Meier C, Weil T, Ständker L, Forssmann WG, Roan NR, Greene WC, Kirchhoff F, Münch J. J Virol. 2012 Jan; 86(2):1244-9.
• Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. Wissing S, Muñoz-Lopez M, Macia A, Yang Z, Montano M, Collins W, Garcia-Perez JL, Moran JV, Greene WC. Hum Mol Genet. 2012 Jan 01; 21(1):208-18.
• Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. Smith DS, Guo K, Barrett BS, Heilman KJ, Evans LH, Hasenkrug KJ, Greene WC, Santiago ML. PLoS Pathog. 2011 Oct; 7(10):e1002284.
• HIV latency. Siliciano RF, Greene WC. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a007096.
• Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. Wissing S, Montano M, Garcia-Perez JL, Moran JV, Greene WC. J Biol Chem. 2011 Oct 21; 286(42):36427-37.
• Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). Sakane N, Kwon HS, Pagans S, Kaehlcke K, Mizusawa Y, Kamada M, Lassen KG, Chan J, Greene WC, Schnoelzer M, Ott M. PLoS Pathog. 2011 Aug; 7(8):e1002184.
• NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Chan JK, Greene WC. Curr Opin HIV AIDS. 2011 Jan; 6(1):12-8.
• Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, Hebbeler AM, Greene WC. Cell. 2010 Nov 24; 143(5):789-801.
• HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, Levy JA, Palefsky JM. Virology. 2011 Jan 20; 409(2):211-22.
• Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. Santiago ML, Smith DS, Barrett BS, Montano M, Benitez RL, Pelanda R, Hasenkrug KJ, Greene WC. J Virol. 2011 Jan; 85(1):189-99.
• Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. Lassen KG, Wissing S, Lobritz MA, Santiago M, Greene WC. J Biol Chem. 2010 Sep 17; 285(38):29326-35.
• Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Kim KA, Yolamanova M, Zirafi O, Roan NR, Staendker L, Forssmann WG, Burgener A, Dejucq-Rainsford N, Hahn BH, Shaw GM, Greene WC, Kirchhoff F, Münch J. Retrovirology. 2010 Jun 23; 7:55.
• Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. Santiago ML, Benitez RL, Montano M, Hasenkrug KJ, Greene WC. J Immunol. 2010 Jul 15; 185(2):1114-23.
• HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Wissing S, Galloway NL, Greene WC. Mol Aspects Med. 2010 Oct; 31(5):383-97.
• Measuring HIV fusion mediated by envelopes from primary viral isolates. Cavrois M, Neidleman J, Galloway N, Derdeyn CA, Hunter E, Greene WC. Methods. 2011 Jan; 53(1):34-8.
• Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). Roan NR, Sowinski S, Münch J, Kirchhoff F, Greene WC. J Biol Chem. 2010 Jan 15; 285(3):1861-9.
• APOBEC3G: an intracellular centurion. Chiu YL, Greene WC. Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12; 364(1517):689-703.
• The challenge of finding a cure for HIV infection. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. Science. 2009 Mar 06; 323(5919):1304-7.
• Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. Michel N, Goffinet C, Ganter K, Allespach I, Kewalramani VN, Saifuddin M, Littman DR, Greene WC, Goldsmith MA, Keppler OT. Retrovirology. 2009 Jan 13; 6:2.
• Unsung hero Robert C. Gallo. Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D. Science. 2009 Jan 09; 323(5911):206-7.
• Guidelines for naming nonprimate APOBEC3 genes and proteins. LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jónsson SR, Landau NR, Löchelt M, Malik HS, Malim MH, Münk C, O'Brien SJ, Pathak VK, Strebel K, Wain-Hobson S, Yu XF, Yuhki N, Harris RS. J Virol. 2009 Jan; 83(2):494-7.
• The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. Roan NR, Münch J, Arhel N, Mothes W, Neidleman J, Kobayashi A, Smith-McCune K, Kirchhoff F, Greene WC. J Virol. 2009 Jan; 83(1):73-80.
• Novel targets for HIV therapy. Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W, Buckheit RW, Esté JA, Cihlar T. Antiviral Res. 2008 Dec; 80(3):251-65.
• Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC. Science. 2008 Sep 05; 321(5894):1343-6.
• HIV vaccine research: the way forward. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. Science. 2008 Jul 25; 321(5888):530-2.
• The achilles heel of the trojan horse model of HIV-1 trans-infection. Cavrois M, Neidleman J, Greene WC. PLoS Pathog. 2008 Jun 27; 4(6):e1000051.
• Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, Schnolzer M, McBurney MW, Marmorstein R, Greene WC, Ott M. Cell Host Microbe. 2008 Mar 13; 3(3):158-67.
• The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Chiu YL, Greene WC. Annu Rev Immunol. 2008; 26:317-53.
• A seminal finding for understanding HIV transmission. Roan NR, Greene WC. Cell. 2007 Dec 14; 131(6):1044-6.
• A history of AIDS: looking back to see ahead. Greene WC. Eur J Immunol. 2007 Nov; 37 Suppl 1:S94-102.
• Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Goffinet C, Michel N, Allespach I, Tervo HM, Hermann V, Kräusslich HG, Greene WC, Keppler OT. Retrovirology. 2007 Jul 26; 4:53.
• Regulation of HIV-1 latency by T-cell activation. Williams SA, Greene WC. Cytokine. 2007 Jul; 39(1):63-74.
• The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, Lewin SR, Gorry PR, Jaworowski A, Greene WC, Sonza S, Crowe SM. J Immunol. 2007 May 15; 178(10):6581-9.
• Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. Williams SA, Kwon H, Chen LF, Greene WC. J Virol. 2007 Jun; 81(11):6043-56.
• APOBEC3G and HIV-1: strike and counterstrike. Soros VB, Greene WC. Curr HIV/AIDS Rep. 2007 Feb; 4(1):3-9.
• Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. Soros VB, Yonemoto W, Greene WC. PLoS Pathog. 2007 Feb; 3(2):e15.
• In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. Cavrois M, Neidleman J, Kreisberg JF, Greene WC. PLoS Pathog. 2007 Jan; 3(1):e4.
• Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. J Biol Chem. 2007 Feb 09; 282(6):3539-46.
• A plea for justice for jailed medical workers. Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA. Science. 2006 Nov 10; 314(5801):924-5.
• High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, Esnault C, Heidmann T, Greene WC. Proc Natl Acad Sci U S A. 2006 Oct 17; 103(42):15588-93.
• NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. O'Mahony A, Raber J, Montano M, Foehr E, Han V, Lu SM, Kwon H, LeFevour A, Chakraborty-Sett S, Greene WC. Mol Cell Biol. 2006 Oct; 26(19):7283-98.
• Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V. J Virol. 2006 Nov; 80(21):10407-18.
• APOBEC3G and HIV-1: strike and counterstrike. Soros VB, Greene WC. Curr Infect Dis Rep. 2006 Jun; 8(4):317-23.
• Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Chiu YL, Greene WC. Trends Immunol. 2006 Jun; 27(6):291-7.
• Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. Kreisberg JF, Yonemoto W, Greene WC. J Exp Med. 2006 Apr 17; 203(4):865-70.
• Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. J Biol Chem. 2006 Jun 02; 281(22):15099-109.
• Human immunodeficiency virus fusion to dendritic cells declines as cells mature. Cavrois M, Neidleman J, Kreisberg JF, Fenard D, Callebaut C, Greene WC. J Virol. 2006 Feb; 80(4):1992-9.
• APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. Chiu YL, Greene WC. J Biol Chem. 2006 Mar 31; 281(13):8309-12.
• NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. EMBO J. 2006 Jan 11; 25(1):139-49.
• Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. Fenard D, Yonemoto W, de Noronha C, Cavrois M, Williams SA, Greene WC. J Immunol. 2005 Nov 01; 175(9):6050-7.
• NF-kappaB RelA phosphorylation regulates RelA acetylation. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, Buckbinder L, Greene WC. Mol Cell Biol. 2005 Sep; 25(18):7966-75.
• Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. Kwon H, Ogle L, Benitez B, Bohuslav J, Montano M, Felsher DW, Greene WC. J Biol Chem. 2005 Oct 21; 280(42):35713-22.
• Assessing acetylation of NF-kappaB. Chen LF, Greene WC. Methods. 2005 Aug; 36(4):368-75.
• Host factors regulating post-integration latency of HIV. Williams SA, Greene WC. Trends Microbiol. 2005 Apr; 13(4):137-9.
• Protecting APOBEC3G: a potential new target for HIV drug discovery. Stopak K, Greene WC. Curr Opin Investig Drugs. 2005 Feb; 6(2):141-7.
• Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. Keppler OT, Allespach I, Schüller L, Fenard D, Greene WC, Fackler OT. J Virol. 2005 Feb; 79(3):1655-65.
• Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. Yonezawa A, Cavrois M, Greene WC. J Virol. 2005 Jan; 79(2):918-26.
• HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Cavrois M, Neidleman J, Yonemoto W, Fenard D, Greene WC. Virology. 2004 Oct 10; 328(1):36-44.
• The brightening future of HIV therapeutics. Greene WC. Nat Immunol. 2004 Sep; 5(9):867-71.
• Redistricting the retroviral restriction factors. Greene WC. Nat Med. 2004 Aug; 10(8):778-80.
• Prostratin antagonizes HIV latency by activating NF-kappaB. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC. J Biol Chem. 2004 Oct 01; 279(40):42008-17.
• Shaping the nuclear action of NF-kappaB. Chen LF, Greene WC. Nat Rev Mol Cell Biol. 2004 May; 5(5):392-401.
• p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC. J Biol Chem. 2004 Jun 18; 279(25):26115-25.
• Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. O'Mahony AM, Montano M, Van Beneden K, Chen LF, Greene WC. J Biol Chem. 2004 Apr 30; 279(18):18137-45.
• Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. Schaeffer E, Soros VB, Greene WC. J Virol. 2004 Feb; 78(3):1375-83.
• Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Cavrois M, Neidleman J, Bigos M, Greene WC. Methods Mol Biol. 2004; 263:333-44.
• How resting T cells deMURR HIV infection. Greene WC. Nat Immunol. 2004 Jan; 5(1):18-9.
• Regulation of NF-kappaB action by reversible acetylation. Greene WC, Chen LF. Novartis Found Symp. 2004; 259:208-17; discussion 218-25.
• HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Stopak K, de Noronha C, Yonemoto W, Greene WC. Mol Cell. 2003 Sep; 12(3):591-601.
• Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. Chen LF, Greene WC. J Mol Med (Berl). 2003 Sep; 81(9):549-57.
• Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. Zander K, Sherman MP, Tessmer U, Bruns K, Wray V, Prechtel AT, Schubert E, Henklein P, Luban J, Neidleman J, Greene WC, Schubert U. J Biol Chem. 2003 Oct 31; 278(44):43202-13.
• Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. Sherman MP, de Noronha CM, Eckstein LA, Hataye J, Mundt P, Williams SA, Neidleman JA, Goldsmith MA, Greene WC. J Virol. 2003 Jul; 77(13):7582-9.
• Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. Stoddart CA, Geleziunas R, Ferrell S, Linquist-Stepps V, Moreno ME, Bare C, Xu W, Yonemoto W, Bresnahan PA, McCune JM, Greene WC. J Virol. 2003 Feb; 77(3):2124-33.
• Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. Chen LF, Mu Y, Greene WC. EMBO J. 2002 Dec 02; 21(23):6539-48.
• HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, Henklein P, Greene WC. Virology. 2002 Oct 10; 302(1):95-105.
• A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Cavrois M, De Noronha C, Greene WC. Nat Biotechnol. 2002 Nov; 20(11):1151-4.
• Insights into the biology of HIV-1 viral protein R. Sherman MP, De Noronha CM, Williams SA, Greene WC. DNA Cell Biol. 2002 Sep; 21(9):679-88.
• Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Greene WC, Peterlin BM. Nat Med. 2002 Jul; 8(7):673-80.
• Slipping through the door: HIV entry into the nucleus. Sherman MP, Greene WC. Microbes Infect. 2002 Jan; 4(1):67-73.
• HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Goldsmith MA. J Exp Med. 2001 Nov 19; 194(10):1407-19.
• Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, Goldman RD, Greene WC. Science. 2001 Nov 02; 294(5544):1105-8.
• Duration of nuclear NF-kappaB action regulated by reversible acetylation. Fischle W, Verdin E, Greene WC. Science. 2001 Aug 31; 293(5535):1653-7.
• HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. Nature. 2001 Apr 12; 410(6830):834-8.
• Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. Schaeffer E, Geleziunas R, Greene WC. J Virol. 2001 Mar; 75(6):2993-3000.
• Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC. J Virol. 2001 Feb; 75(3):1522-32.
• The NF-kappa B-inducing kinase induces PC12 cell differentiation and prevents apoptosis. Foehr ED, Bohuslav J, Chen LF, DeNoronha C, Geleziunas R, Lin X, O'Mahony A, Greene WC. J Biol Chem. 2000 Nov 03; 275(44):34021-4.
• NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells. Foehr ED, Lin X, O'Mahony A, Geleziunas R, Bradshaw RA, Greene WC. J Neurosci. 2000 Oct 15; 20(20):7556-63.
• Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, de Noronha CM, Greene WC, Wray V, Schubert U. J Biol Chem. 2000 Oct 13; 275(41):32016-26.
• Cotranslational dimerization of the Rel homology domain of NF-kappaB1 generates p50-p105 heterodimers and is required for effective p50 production. Lin L, DeMartino GN, Greene WC. EMBO J. 2000 Sep 01; 19(17):4712-22.
• Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. Sherman MP, de Noronha CM, Pearce D, Greene WC. J Virol. 2000 Sep; 74(17):8159-65.
• Protein kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta. Lin X, O'Mahony A, Mu Y, Geleziunas R, Greene WC. Mol Cell Biol. 2000 Apr; 20(8):2933-40.
• Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. O'Mahony A, Lin X, Geleziunas R, Greene WC. Mol Cell Biol. 2000 Feb; 20(4):1170-8.
• The generation of nfkb2 p52: mechanism and efficiency. Heusch M, Lin L, Geleziunas R, Greene WC. Oncogene. 1999 Nov 04; 18(46):6201-8.
• Cutting edge: SIV Nef protein utilizes both leucine- and tyrosine-based protein sorting pathways for down-regulation of CD4. Bresnahan PA, Yonemoto W, Greene WC. J Immunol. 1999 Sep 15; 163(6):2977-81.
• The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases. Lin X, Cunningham ET, Mu Y, Geleziunas R, Greene WC. Immunity. 1999 Feb; 10(2):271-80.
• Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways. Jenkins Y, McEntee M, Weis K, Greene WC. J Cell Biol. 1998 Nov 16; 143(4):875-85.
• A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Bresnahan PA, Yonemoto W, Ferrell S, Williams-Herman D, Geleziunas R, Greene WC. Curr Biol. 1998 Nov 05; 8(22):1235-8.
• Molecular determinants of NF-kappaB-inducing kinase action. Lin X, Mu Y, Cunningham ET, Marcu KB, Geleziunas R, Greene WC. Mol Cell Biol. 1998 Oct; 18(10):5899-907.
• Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors. Liegler TJ, Yonemoto W, Elbeik T, Vittinghoff E, Buchbinder SP, Greene WC. J Infect Dis. 1998 Sep; 178(3):669-79.
• Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases. Geleziunas R, Ferrell S, Lin X, Mu Y, Cunningham ET, Grant M, Connelly MA, Hambor JE, Marcu KB, Greene WC. Mol Cell Biol. 1998 Sep; 18(9):5157-65.
• Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. Lin L, DeMartino GN, Greene WC. Cell. 1998 Mar 20; 92(6):819-28.
• Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Liu KD, Gaffen SL, Goldsmith MA, Greene WC. Curr Biol. 1997 Nov 01; 7(11):817-26.
• The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. Ghoda L, Lin X, Greene WC. J Biol Chem. 1997 Aug 22; 272(34):21281-8.
• Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity. Miller MD, Warmerdam MT, Ferrell SS, Benitez R, Greene WC. Virology. 1997 Aug 04; 234(2):215-25.
• HIV Rev-dependent binding of SF2/ASF to the Rev response element: possible role in Rev-mediated inhibition of HIV RNA splicing. Powell DM, Amaral MC, Wu JY, Maniatis T, Greene WC. Proc Natl Acad Sci U S A. 1997 Feb 04; 94(3):973-8.
• Interaction of the human T-lymphotropic virus type 1 Tax dimer with CREB and the viral 21-base-pair repeat. Tie F, Adya N, Greene WC, Giam CZ. J Virol. 1996 Dec; 70(12):8368-74.
• Unraveling the function of HIV type 1 Nef. Geleziunas R, Miller MD, Greene WC. AIDS Res Hum Retroviruses. 1996 Nov 20; 12(17):1579-82.
• c-rel regulation of IL-2 gene expression may be mediated through activation of AP-1. Shapiro VS, Mollenauer MN, Greene WC, Weiss A. J Exp Med. 1996 Nov 01; 184(5):1663-9.
• Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity. Gaffen SL, Lai SY, Ha M, Liu X, Hennighausen L, Greene WC, Goldsmith MA. J Biol Chem. 1996 Aug 30; 271(35):21381-90.
• Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors. Kim JH, McLinden RJ, Mosca JD, Vahey MT, Greene WC, Redfield RR. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 01; 12(4):343-51.
• The alpha chain of the IL-2 receptor determines the species specificity of high-affinity IL-2 binding. Liu KD, Greene WC, Goldsmith MA. Cytokine. 1996 Aug; 8(8):613-21.
• Denying HIV safe haven. Greene WC. N Engl J Med. 1996 May 09; 334(19):1264-5.
• Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Hsu DK, Hammes SR, Kuwabara I, Greene WC, Liu FT. Am J Pathol. 1996 May; 148(5):1661-70.
• Is the Nef protein of HIV-1 required for pathogenesis? Miller MD, Greene WC. Trends Microbiol. 1996 May; 4(5):171-2; discussion 173.
• Both amino- and carboxyl-terminal sequences within I kappa B alpha regulate its inducible degradation. Sun S, Elwood J, Greene WC. Mol Cell Biol. 1996 Mar; 16(3):1058-65.
• The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes. Lai SY, Xu W, Gaffen SL, Liu KD, Longmore GD, Greene WC, Goldsmith MA. Proc Natl Acad Sci U S A. 1996 Jan 09; 93(1):231-5.
• Interaction of HTLV-I Tax with the human proteasome: implications for NF-kappa B induction. Béraud C, Greene WC. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 13 Suppl 1:S76-84.
• Analysis of interleukin-2-dependent signal transduction through the Shc/Grb2 adapter pathway. Interleukin-2-dependent mitogenesis does not require Shc phosphorylation or receptor association. Evans GA, Goldsmith MA, Johnston JA, Xu W, Weiler SR, Erwin R, Howard OM, Abraham RT, O'Shea JJ, Greene WC. J Biol Chem. 1995 Dec 01; 270(48):28858-63.
• Predicting progression to AIDS. Greene WC. Ann Intern Med. 1995 Nov 01; 123(9):726-7.
• Identification of a variable region within the cytoplasmic tail of the IL-2 receptor beta chain that is required for growth signal transduction. Liu KD, Lai SY, Goldsmith MA, Greene WC. J Biol Chem. 1995 Sep 22; 270(38):22176-81.
• Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the gamma c chain. Goldsmith MA, Lai SY, Xu W, Amaral MC, Kuczek ES, Parent LJ, Mills GB, Tarr KL, Longmore GD, Greene WC. J Biol Chem. 1995 Sep 15; 270(37):21729-37.
• Signaling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA-binding activity. Gaffen SL, Lai SY, Xu W, Gouilleux F, Groner B, Goldsmith MA, Greene WC. Proc Natl Acad Sci U S A. 1995 Aug 01; 92(16):7192-6.
• Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. Goldsmith MA, Warmerdam MT, Atchison RE, Miller MD, Greene WC. J Virol. 1995 Jul; 69(7):4112-21.
• Ligand binding by the IL-2 receptor is modulated by intracellular determinants of the IL-2 receptor beta-chain. Goldsmith MA, Amaral MC, Greene WC. J Immunol. 1995 Mar 01; 154(5):2033-40.
• Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. Miller MD, Warmerdam MT, Page KA, Feinberg MB, Greene WC. J Virol. 1995 Jan; 69(1):579-84.
• Human T-cell leukemia virus type I Tax activation of NF-kappa B/Rel involves phosphorylation and degradation of I kappa B alpha and RelA (p65)-mediated induction of the c-rel gene. Sun SC, Elwood J, Béraud C, Greene WC. Mol Cell Biol. 1994 Nov; 14(11):7377-84.
• The HIV-1 nef gene acts as a positive viral infectivity factor. Miller MD, Feinberg MB, Greene WC. Trends Microbiol. 1994 Aug; 2(8):294-8.
• The cytoplasmic domain of the interleukin-2 receptor beta chain contains both unique and functionally redundant signal transduction elements. Goldsmith MA, Xu W, Amaral MC, Kuczek ES, Greene WC. J Biol Chem. 1994 May 20; 269(20):14698-704.
• The membrane proximal segment of the IL-2 receptor beta-chain acidic region is essential for IL2-dependent protein tyrosine kinase activation. Williamson P, Merida I, Greene WC, Gaulton G. Leukemia. 1994 Apr; 8 Suppl 1:S186-9.
• Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Sun SC, Ganchi PA, Béraud C, Ballard DW, Greene WC. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1346-50.
• Human T-cell leukemia virus type I Tax associates with and is negatively regulated by the NF-kappa B2 p100 gene product: implications for viral latency. Béraud C, Sun SC, Ganchi P, Ballard DW, Greene WC. Mol Cell Biol. 1994 Feb; 14(2):1374-82.
• The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. J Exp Med. 1994 Jan 01; 179(1):101-13.
• A novel NF-kappa B complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerization. Ganchi PA, Sun SC, Greene WC, Ballard DW. Mol Cell Biol. 1993 Dec; 13(12):7826-35.
• Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P, Herrlich P. EMBO J. 1993 Oct; 12(10):3879-91.
• AIDS and the immune system. Greene WC. Sci Am. 1993 Sep; 269(3):98-105.
• Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo. Bogerd H, Greene WC. J Virol. 1993 May; 67(5):2496-502.
• Unexpected effects of the IL-2 receptor alpha subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog. Kuziel WA, Ju G, Grdina TA, Greene WC. J Immunol. 1993 Apr 15; 150(8 Pt 1):3357-65.
• NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Sun SC, Ganchi PA, Ballard DW, Greene WC. Science. 1993 Mar 26; 259(5103):1912-5.
• The serine-rich cytoplasmic domain of the interleukin-2 receptor beta chain is essential for interleukin-2-dependent tyrosine protein kinase and phosphatidylinositol-3-kinase activation. Merida I, Williamson P, Kuziel WA, Greene WC, Gaulton GN. J Biol Chem. 1993 Mar 25; 268(9):6765-70.
• Multiple arginine residues within the basic domain of HTLV-I Rex are required for specific RNA binding and function. Hammes SR, Greene WC. Virology. 1993 Mar; 193(1):41-9.
• The c-rel protooncogene product represses NF-kappa B p65-mediated transcriptional activation of the long terminal repeat of type 1 human immunodeficiency virus. Doerre S, Sista P, Sun SC, Ballard DW, Greene WC. Proc Natl Acad Sci U S A. 1993 Feb 01; 90(3):1023-7.
• I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Ganchi PA, Sun SC, Greene WC, Ballard DW. Mol Biol Cell. 1992 Dec; 3(12):1339-52.
• Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. Mills GB, Arima N, May C, Hill M, Schmandt R, Li J, Miyamoto NG, Greene WC. Int Immunol. 1992 Nov; 4(11):1233-43.
• Molecular insights into human immunodeficiency virus type 1 pathogenesis. Feinberg MB, Greene WC. Curr Opin Immunol. 1992 Aug; 4(4):466-74.
• The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. Walker WH, Stein B, Ganchi PA, Hoffman JA, Kaufman PA, Ballard DW, Hannink M, Greene WC. J Virol. 1992 Aug; 66(8):5018-29.
• Dominant-negative mutants are clustered in a domain of the human T-cell leukemia virus type I Rex protein: implications for trans dominance. Weichselbraun I, Berger J, Dobrovnik M, Bogerd H, Grassmann R, Greene WC, Hauber J, Böhnlein E. J Virol. 1992 Jul; 66(7):4540-5.
• IL-2-induced signal transduction involves the activation of nuclear NF-kappa B expression. Arima N, Kuziel WA, Grdina TA, Greene WC. J Immunol. 1992 Jul 01; 149(1):83-91.
• Nuclear expression of the 50- and 65-kD Rel-related subunits of nuclear factor-kappa B is differentially regulated in human monocytic cells. Kaufman PA, Weinberg JB, Greene WC. J Clin Invest. 1992 Jul; 90(1):121-9.
• Characterization of a novel nuclear localization signal in the HTLV-I tax transactivator protein. Smith MR, Greene WC. Virology. 1992 Mar; 187(1):316-20.
• The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Ballard DW, Dixon EP, Peffer NJ, Bogerd H, Doerre S, Stein B, Greene WC. Proc Natl Acad Sci U S A. 1992 Mar 01; 89(5):1875-9.
• Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: evidence for a pretranslational component of regulation. Arima N, Molitor JA, Smith MR, Kim JH, Daitoku Y, Greene WC. J Virol. 1991 Dec; 65(12):6892-9.
• Kappa B-specific DNA binding proteins are differentially inhibited by enhancer mutations and biological oxidation. Molitor JA, Ballard DW, Greene WC. New Biol. 1991 Oct; 3(10):987-96.
• Type I human T cell leukemia virus tax protein transforms rat fibroblasts through the cyclic adenosine monophosphate response element binding protein/activating transcription factor pathway. Smith MR, Greene WC. J Clin Invest. 1991 Sep; 88(3):1038-42.
• The type I human T-cell leukemia virus (HTLV-I) Rex trans-activator binds directly to the HTLV-I Rex and the type 1 human immunodeficiency virus Rev RNA response elements. Bogerd HP, Huckaby GL, Ahmed YF, Hanly SM, Greene WC. Proc Natl Acad Sci U S A. 1991 Jul 01; 88(13):5704-8.
• A member of the set of kappa B binding proteins, HIVEN86A, is a product of the human c-rel proto-oncogene. Lee JH, Li YC, Doerre S, Sista P, Ballard DW, Greene WC, Franza BR. Oncogene. 1991 Apr; 6(4):665-7.
• Kappa B binding proteins are constitutively expressed in an IL-2 autocrine human T cell line. Hémar A, Cereghini S, Cornet V, Blank V, Israël A, Greene WC, Dautry-Varsat A. J Immunol. 1991 Apr 01; 146(7):2409-16.
• Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia. Smith MR, Greene WC. J Clin Invest. 1991 Mar; 87(3):761-6.
• The HTLV-I Rex response element mediates a novel form of mRNA polyadenylation. Ahmed YF, Gilmartin GM, Hanly SM, Nevins JR, Greene WC. Cell. 1991 Feb 22; 64(4):727-37.
• The molecular biology of human immunodeficiency virus type 1 infection. Greene WC. N Engl J Med. 1991 Jan 31; 324(5):308-17.
• Functional analyses of the type I human T-cell leukemia virus tax gene product. Smith MR, Greene WC. Trans Assoc Am Physicians. 1991; 104:78-91.
• Rex transregulation of human T-cell leukemia virus type II gene expression. Kim JH, Kaufman PA, Hanly SM, Rimsky LT, Greene WC. J Virol. 1991 Jan; 65(1):405-14.
• NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Molitor JA, Walker WH, Doerre S, Ballard DW, Greene WC. Proc Natl Acad Sci U S A. 1990 Dec; 87(24):10028-32.
• The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Ballard DW, Walker WH, Doerre S, Sista P, Molitor JA, Dixon EP, Peffer NJ, Hannink M, Greene WC. Cell. 1990 Nov 16; 63(4):803-14.
• Identification of HTLV-I tax trans-activator mutants exhibiting novel transcriptional phenotypes. Smith MR, Greene WC. Genes Dev. 1990 Nov; 4(11):1875-85.
• Functions of the auxiliary gene products of the human immunodeficiency virus type 1. Cullen BR, Greene WC. Virology. 1990 Sep; 178(1):1-5.
• The molecular basis for the generation of the human soluble interleukin 2 receptor. Rubin LA, Galli F, Greene WC, Nelson DL, Jay G. Cytokine. 1990 Sep; 2(5):330-6.
• Interleukin-2 and the IL-2 receptor: new insights into structure and function. Kuziel WA, Greene WC. J Invest Dermatol. 1990 Jun; 94(6 Suppl):27S-32S.
• Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Ahmed YF, Hanly SM, Malim MH, Cullen BR, Greene WC. Genes Dev. 1990 Jun; 4(6):1014-22.
• The human interleukin-2 receptor: insights into subunit structure and growth signal transduction. Fung MR, Greene WC. Semin Immunol. 1990 Mar; 2(2):119-28.
• Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor beta is tyrosine phosphorylated. Mills GB, May C, McGill M, Fung M, Baker M, Sutherland R, Greene WC. J Biol Chem. 1990 Feb 25; 265(6):3561-7.
• Regulation of HIV-1 gene expression. Greene WC. Annu Rev Immunol. 1990; 8:453-75.
• A second sequence element located 3' to the NF-kappa B-binding site regulates IL-2 receptor-alpha gene induction. Pomerantz JL, Mauxion F, Yoshida M, Greene WC, Sen R. J Immunol. 1989 Dec 15; 143(12):4275-81.
• Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Hammes SR, Dixon EP, Malim MH, Cullen BR, Greene WC. Proc Natl Acad Sci U S A. 1989 Dec; 86(23):9549-53.
• The same 50-kDa cellular protein binds to the negative regulatory elements of the interleukin 2 receptor alpha-chain gene and the human immunodeficiency virus type 1 long terminal repeat. Smith MR, Greene WC. Proc Natl Acad Sci U S A. 1989 Nov; 86(21):8526-30.
• Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator. Rimsky L, Dodon MD, Dixon EP, Greene WC. Nature. 1989 Oct 05; 341(6241):453-6.
• Activation of the interleukin-2 receptor alpha gene: regulatory role for DNA-protein interactions flanking the kappa B enhancer. Ballard DW, Böhnlein E, Hoffman JA, Bogerd HP, Dixon EP, Franza BR, Greene WC. New Biol. 1989 Oct; 1(1):83-92.
• Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Hanly SM, Rimsky LT, Malim MH, Kim JH, Hauber J, Duc Dodon M, Le SY, Maizel JV, Cullen BR, Greene WC. Genes Dev. 1989 Oct; 3(10):1534-44.
• Regulatory pathways governing HIV-1 replication. Cullen BR, Greene WC. Cell. 1989 Aug 11; 58(3):423-6.
• HIV-1, HTLV-1 and normal T-cell growth: transcriptional strategies and surprises. Greene WC, Böhnlein E, Ballard DW. Immunol Today. 1989 Aug; 10(8):272-8.
• Induction of interleukin-2 receptor-alpha gene expression is regulated by post-translational activation of kappa B specific DNA binding proteins. Böhnlein E, Ballard DW, Bogerd H, Peffer NJ, Lowenthal JW, Greene WC. J Biol Chem. 1989 May 25; 264(15):8475-8.
• Tumor necrosis factor-alpha activation of the IL-2 receptor-alpha gene involves the induction of kappa B-specific DNA binding proteins. Lowenthal JW, Ballard DW, Bogerd H, Böhnlein E, Greene WC. J Immunol. 1989 May 01; 142(9):3121-8.
• Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Hoyos B, Ballard DW, Böhnlein E, Siekevitz M, Greene WC. Science. 1989 Apr 28; 244(4903):457-60.
• Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins. Böhnlein E, Siekevitz M, Ballard DW, Lowenthal JW, Rimsky L, Bogérd H, Hoffman J, Wano Y, Franza BR, Greene WC. J Virol. 1989 Apr; 63(4):1578-86.
• Tumor necrosis factor alpha induces proteins that bind specifically to kappa B-like enhancer elements and regulate interleukin 2 receptor alpha-chain gene expression in primary human T lymphocytes. Lowenthal JW, Ballard DW, Böhnlein E, Greene WC. Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2331-5.
• HIV-1, HTLV-I and the interleukin-2 receptor: insights into transcriptional control. Böhnlein E, Lowenthal JW, Wano Y, Franza BR, Ballard DW, Greene WC. Haematol Blood Transfus. 1989; 32:393-401.
• Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth. Wano Y, Feinberg M, Hosking JB, Bogerd H, Greene WC. Proc Natl Acad Sci U S A. 1988 Dec; 85(24):9733-7.
• Co-internalization of the p55 and p70 subunits of the high-affinity human interleukin 2 receptor. Evidence for a stable ternary receptor complex. Fung MR, Ju G, Greene WC. J Exp Med. 1988 Nov 01; 168(5):1923-8.
• Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Rimsky L, Hauber J, Dukovich M, Malim MH, Langlois A, Cullen BR, Greene WC. Nature. 1988 Oct 20; 335(6192):738-40.
• Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Collins L, Tsien WH, Seals C, Hakimi J, Weber D, Bailon P, Hoskings J, Greene WC, Toome V, Ju G. Proc Natl Acad Sci U S A. 1988 Oct; 85(20):7709-13.
• HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Ballard DW, Böhnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. Science. 1988 Sep 23; 241(4873):1652-5.
• p55 IL-2 receptor mRNA precursors in murine T lymphocyte nuclei. Froussard P, Chastagner P, Sommé G, Abadie A, Greene W, Thèze J, Longacre S. J Immunol. 1988 Aug 15; 141(4):1358-64.
• The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Böhnlein E, Lowenthal JW, Siekevitz M, Ballard DW, Franza BR, Greene WC. Cell. 1988 Jun 03; 53(5):827-36.
• Regulation of interleukin 2 receptor alpha subunit (Tac or CD25 antigen) gene expression: binding of inducible nuclear proteins to discrete promoter sequences correlates with transcriptional activation. Lowenthal JW, Böhnlein E, Ballard DW, Greene WC. Proc Natl Acad Sci U S A. 1988 Jun; 85(12):4468-72.
• Sequence requirements for ligand binding and cell surface expression of the Tac antigen, a human interleukin-2 receptor. Cullen BR, Podlaski FJ, Peffer NJ, Hosking JB, Greene WC. J Biol Chem. 1988 Apr 05; 263(10):4900-6.
• Sarcoidosis and interleukin-2 receptors. Greene WC. Am Rev Respir Dis. 1988 Apr; 137(4):757-8.
• Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation. Zeitz M, Greene WC, Peffer NJ, James SP. Gastroenterology. 1988 Mar; 94(3):647-55.
• In: Gallin J, Goldstein I, Snyderman R (Eds.), Inflammation: Basic principles and clinical correlations Greene WC. . IL-2, IL-2 receptors, and the growth of human T cells. 1988; 209-288.
• In: Smith KA (Ed.), Interleukin 2 Wano Y, Dukovich M, Kehrl JH, Greene WC. . New perspectives on the structure of the human high affinity i nterleukin-2 receptor. 1988; 99-112.
• New insights into the structure of high-affinity interleukin-2 receptors. Greene WC, Wano YJ, Dukovich M. Recent Prog Horm Res. 1988; 44:141-55.
• Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. Kehrl JH, Dukovich M, Whalen G, Katz P, Fauci AS, Greene WC. J Clin Invest. 1988 Jan; 81(1):200-5.
• The human interleukin-2 receptor. Recent studies of structure and regulation. Greene WC, Böhnlein E, Siekevitz M, Franza BR, Lowenthal J. Ann N Y Acad Sci. 1988; 546:116-21.
• Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Science. 1987 Dec 11; 238(4833):1575-8.
• Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor. Lowenthal JW, Greene WC. J Exp Med. 1987 Oct 01; 166(4):1156-61.
• Reconstitution of a functional interleukin 2 receptor in a nonlymphoid cell. Rubin LA, Hoekzema GS, Nelson DL, Greene WC, Jay G. J Immunol. 1987 Oct 01; 139(7):2355-60.
• Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein. Bich-Thuy LT, Dukovich M, Peffer NJ, Fauci AS, Kehrl JH, Greene WC. J Immunol. 1987 Sep 01; 139(5):1550-6.
• Interleukin 1 gene expression in adult T cell leukemia. Wano Y, Hattori T, Matsuoka M, Takatsuki K, Chua AO, Gubler U, Greene WC. J Clin Invest. 1987 Sep; 80(3):911-6.
• The human interleukin-2 receptor: a molecular and biochemical analysis of structure and function. Greene WC. Clin Res. 1987 Sep; 35(5):439-50.
• Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Siekevitz M, Feinberg MB, Holbrook N, Wong-Staal F, Greene WC. Proc Natl Acad Sci U S A. 1987 Aug; 84(15):5389-93.
• A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Dukovich M, Wano Y, Katz P, Cullen BR, Kehrl JH, Greene WC. Nature. 1987 Jun 11-17; 327(6122):518-22.
• Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. Holter W, Goldman CK, Casabo L, Nelson DL, Greene WC, Waldmann TA. J Immunol. 1987 May 01; 138(9):2917-22.
• High-affinity interleukin 2 binding by an oncogenic hybrid interleukin 2-epidermal growth factor receptor molecule. Bernard O, Fazekas de St Groth B, Ullrich A, Green W, Schlessinger J. Proc Natl Acad Sci U S A. 1987 Apr; 84(8):2125-9.
• Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Robb RJ, Rusk CM, Yodoi J, Greene WC. Proc Natl Acad Sci U S A. 1987 Apr; 84(7):2002-6.
• Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. Robb RJ, Greene WC. J Exp Med. 1987 Apr 01; 165(4):1201-6.
• Reconstitution of high affinity IL-2 receptor expression in a human T-cell line using a retroviral cDNA expression vector. Wano Y, Cullen BR, Svetlik PA, Peffer NJ, Greene WC. Mol Biol Med. 1987 Apr; 4(2):95-109.
• Trans-activator gene of HTLV-II: interpretation. Greene WC, Leonard WJ, Wano Y, Svetlik PB, Peffer NJ, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. Science. 1987 Feb 27; 235(4792):1073.
• An overview of the human interleukin-2 receptor: molecular, biochemical, and functional properties. Greene WC. Cancer Invest. 1987; 5(4):369-76.
• Human interleukin 2 receptor (Tac antigen). Greene WC, Leonard WJ. Methods Enzymol. 1987; 150:682-700.
• In: Pruzanki W, Seligmann M (Eds.), Clinical Immunology Greene WC, Leonard WJ, Wano Y, Sodroski JG, Rosen CA, Haseltine WA. . The transactivator (tat) gene of HTLV-II induces the expression of cellular genes involved in T cell growth. 1987; 213-216.
• In: Webb DR, Pierce CW, Cohen S (Eds.), Proceedings of the Fifth International Lymphokine Workshop Greene WC, Dukovich M, Wano Y, Kehrl JH, Robb RJ. . The human high affinity for interleukin-2 receptor. 1987; 171-179.
• Int. J. Immunother. III Greene WC. . Expression of interleukin-2 receptors in normal and neoplastic T cells. 1987; 3:171-175.
• Proceedings of the AACR 1987 Greene WC. . IL-2, IL-2 receptors and human retroviruses. 1987; 469-470.
• Expression of human interleukin-2 receptor cDNA in E. coli. Chanda PK, Chen GF, Baine Y, Leonard WJ, Greene WC, Chang TW, Chang NT. Biochem Biophys Res Commun. 1986 Dec 15; 141(2):804-11.
• Diltiazem inhibits transferrin receptor expression and causes G1 arrest in normal and neoplastic T cells. Neckers LM, Bauer S, McGlennen RC, Trepel JB, Rao K, Greene WC. Mol Cell Biol. 1986 Dec; 6(12):4244-50.
• Characterization of the human interleukin 2 receptor at the DNA, RNA, and protein level. Greene WC. Immunobiology. 1986 Sep; 172(3-5):357-64.
• The human interleukin-2 receptor: analysis of structure and function. Greene WC, Depper JM, Krönke M, Leonard WJ. Immunol Rev. 1986 Aug; 92:29-48.
• Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. Krönke M, Schlick E, Waldmann TA, Vitetta ES, Greene WC. Cancer Res. 1986 Jul; 46(7):3295-8.
• A secreted form of the human interleukin 2 receptor encoded by an "anchor minus" cDNA. Treiger BF, Leonard WJ, Svetlik P, Rubin LA, Nelson DL, Greene WC. J Immunol. 1986 Jun 01; 136(11):4099-105.
• Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression. Greene WC, Leonard WJ, Wano Y, Svetlik PB, Peffer NJ, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. Science. 1986 May 16; 232(4752):877-80.
• Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Weissman AM, Harford JB, Svetlik PB, Leonard WL, Depper JM, Waldmann TA, Greene WC, Klausner RD. Proc Natl Acad Sci U S A. 1986 Mar; 83(5):1463-6.
• Growth of human T lymphocytes: an analysis of interleukin 2 and its cellular receptor. Greene WC, Leonard WJ, Depper JM. Prog Hematol. 1986; 14:283-301.
• In: Greene WC, moderator. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T lymphotropic retroviruses. Ann. Int. Med . Deregulated interleukin-2 receptor expression in Adult T-cell Leukemia. 1986; 105:566-569.
• In: Marget M, Lang W, Gabler-Sandberger E (Eds.), Proceedings of the IXth International Congress of Infectious and Parasitic Diseases Greene WC, Leonard WJ, Wano Y, Sodroski JG, Rosen CA, Haseltine WA. . The transactivator (tat) gene of HTLV-II activates IL-2 receptor, IL-2, and class II major histocompatibility complex cellular gene expression. 1986; 1:67-69.
• In: Pincus S, Pisetsky D, Rosenwasser L (Eds.), Biologically based immunomodulators in the therapy of rheumatic diseases Depper JM, Leonard WJ, Greene WC. . The human receptor for interleukin-2: characterization, controversies, and expression in rheumatic diseases. 1986; 297-306.
• The arrangement of immunoglobulin, T cell antigen receptor, and interleukin 2 receptor genes in human lymphoid neoplasms. Waldmann TA, Korsmeyer SJ, Greene WC. Symp Fundam Cancer Res. 1986; 38:63-78.
• The human interleukin-2 receptor. Greene WC, Leonard WJ. Annu Rev Immunol. 1986; 4:69-95.
• The human interleukin-2 receptor: role in normal T-cell growth and association with HTLV-I-induced T-cell leukemia. Greene WC, Depper JM, Krönke M, Leonard WJ. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:731-7.
• Structure of the human interleukin-2 receptor gene. Leonard WJ, Depper JM, Kanehisa M, Krönke M, Peffer NJ, Svetlik PB, Sullivan M, Greene WC. Science. 1985 Nov 08; 230(4726):633-9.
• Monoclonal antibody OKT11A inhibits and recombinant interleukin 2 (IL 2) augments expression of IL 2 receptors at a pretranslational level. Reed JC, Greene WC, Hoover RG, Nowell PC. J Immunol. 1985 Oct; 135(4):2478-82.
• Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Waldmann TA, Longo DL, Leonard WJ, Depper JM, Thompson CB, Krönke M, Goldman CK, Sharrow S, Bongiovanni K, Greene WC. Cancer Res. 1985 Sep; 45(9 Suppl):4559s-4562s.
• Interleukin 2 receptor gene expression in normal human T lymphocytes. Leonard WJ, Krönke M, Peffer NJ, Depper JM, Greene WC. Proc Natl Acad Sci U S A. 1985 Sep; 82(18):6281-5.
• Isolation and expression of complementary DNAs encoding the human interleukin 2 receptor. Greene WC, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, Krönke M, Svetlik P, Peffer NJ, Waldmann TA. Cancer Res. 1985 Sep; 45(9 Suppl):4563s-4567s.
• Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. N Engl J Med. 1985 Jul 11; 313(2):79-84.
• Stable expression of cDNA encoding the human interleukin 2 receptor in eukaryotic cells. Greene WC, Robb RJ, Svetlik PB, Rusk CM, Depper JM, Leonard WJ. J Exp Med. 1985 Jul 01; 162(1):363-8.
• Localization of the gene encoding the human interleukin-2 receptor on chromosome 10. Leonard WJ, Donlon TA, Lebo RV, Greene WC. Science. 1985 Jun 28; 228(4707):1547-9.
• Deregulation of interleukin-2 receptor gene expression in HTLV-I-induced adult T-cell leukemia. Krönke M, Leonard WJ, Depper JM, Greene WC. Science. 1985 Jun 07; 228(4704):1215-7.
• Adult T cell leukemia: a potential target for ricin A chain immunotoxins. Krönke M, Depper JM, Leonard WJ, Vitetta ES, Waldmann TA, Greene WC. Blood. 1985 Jun; 65(6):1416-21.
• Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Depper JM, Leonard WJ, Drogula C, Krönke M, Waldmann TA, Greene WC. Proc Natl Acad Sci U S A. 1985 Jun; 82(12):4230-4.
• Nucleotide sequence and expression of a mouse interleukin 2 receptor cDNA. Miller J, Malek TR, Leonard WJ, Greene WC, Shevach EM, Germain RN. J Immunol. 1985 Jun; 134(6):4212-7.
• Sequential expression of genes involved in human T lymphocyte growth and differentiation. Krönke M, Leonard WJ, Depper JM, Greene WC. J Exp Med. 1985 Jun 01; 161(6):1593-8.
• The human receptor for T-cell growth factor. Evidence for variable post-translational processing, phosphorylation, sulfation, and the ability of precursor forms of the receptor to bind T-cell growth factor. Leonard WJ, Depper JM, Krönke M, Robb RJ, Waldmann TA, Greene WC. J Biol Chem. 1985 Feb 10; 260(3):1872-80.
• Activators of protein kinase C and 5-azacytidine induce IL-2 receptor expression on human T lymphocytes. Depper JM, Leonard WJ, Drogula CL, Krönke M, Waldmann TA, Greene WC. J Cell Biochem. 1985; 27(3):267-76.
• Effect of wheat germ agglutinin on the interleukin pathway of human T lymphocyte activation. Reed JC, Robb RJ, Greene WC, Nowell PC. J Immunol. 1985 Jan; 134(1):314-23.
• In: Cancer Cells 3: Growth factors and transformation Waldmann TA, Leonard WJ, Depper JM, Kronke M, Kozak R, Greene WC. . Structure, function, and expression of the receptor for interleukin-2 on normal and malignant lymphocytes. 1985; 221-226.
• In: Feldman M (Ed.), Human T cell clones: An approach to immune regulation Waldmann TA, Leonard WJ, Depper JM, Kronke M, Goldman CK, Bongiovani KF, Greene WC.. . Interleukin-2 receptors. 1985; 285-300.
• In: Feldmann M, Mitchison NA (Eds.), Immune Regulation Leonard WJ, Depper JM, Crabtee GM, Rudikoff S, Pumphrey J, Robb RJ, Kronke M, Svetlik P, Peffer NJ, Waldmann TA, Greene WC. . Molecular cloning and expression of cDNAs encoding the human interleukin-2 receptor. 1985; 185-195.
• In: Pattengale PK, Lukes RJ, Taylor CR (Eds.), Lymphoproliferative Diseases: Pathogenesis, Diagnosis, and Therapy Greene WC, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, Kronke M, Svetlik P, Peffer NJ, Waldmann TA, Leonard WJ. . Molecular analysis of the human interleukin-2 receptor. 1985; 8-20.
• In: Pinchera A, Doria G, Dammacco F, Bargellesi A (Eds.), Monoclonal Antibodies 1984: Biological and Clinical Applications Waldmann TA, Leonard WJ, Depper JM, Kronke M, Goldman CK, Sharrow S, Greene WC. . Interleukin-2 receptors on lymphocytes. 1985; 329-338.
• In: Sorg C, Schimple A (Eds.), Cellular and molecular biology of lymphokines Kronke M, Depper JM, Leonard WJ, Wong-Staal F, Gallo RC, Waldmann TA, Greene WC. . Cyclosporin A inhibits expression of select T-cell activation genes. 1985; 647-652.
• In: Sorg C, Schimple A (Eds.), Cellular and molecular biology of lymphokines Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, Kronke M, Svetlik P, Peffer NJ, Waldmann TA, Greene WC. . Cloning of cDNAs for the human interleukin-2 receptor and determination of its complete protein sequence. 1985; 623-633.
• In: Sorg P, Schimple A (Eds.), Cellular and molecular biology of lymphokines Depper JM, Leonard WJ, Kronke M, Waldmann TA, Greene WC. . The role of protein kinase C, and effects of 5-azacytidine on regulation on interleukin-2 receptor expression. 1985; 151-156.
• Molecular cloning of cDNA for the human interleukin-2 receptor. Greene WC, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, Krönke M, Svetlik P, Peffer NJ, Waldmann TA. Haematol Blood Transfus. 1985; 29:388-95.
• Receptors for T-cell growth factor: structure, function and expression on normal and neoplastic cells. Greene WC, Robb RJ. Contemp Top Mol Immunol. 1985; 10:1-34.
• The human interleukin-2 receptor. Greene WC, Depper JM, Krönke M, Leonard WJ. J Cell Sci Suppl. 1985; 3:97-106.
• Cellular origin of hairy cell leukemia: malignant B cells that express receptors for T cell growth factor. Korsmeyer SJ, Greene WC, Waldmann TA. Semin Oncol. 1984 Dec; 11(4):394-400.
• Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. Depper JM, Leonard WJ, Krönke M, Noguchi PD, Cunningham RE, Waldmann TA, Greene WC. J Immunol. 1984 Dec; 133(6):3054-61.
• Expression of interleukin 2 receptors on activated human B cells. Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, Sharrow SO, Bongiovanni KF, Korsmeyer SJ, Greene WC. J Exp Med. 1984 Nov 01; 160(5):1450-66.
• Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. Depper JM, Leonard WJ, Krönke M, Waldmann TA, Greene WC. J Immunol. 1984 Oct; 133(4):1691-5.
• Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. Robb RJ, Greene WC, Rusk CM. J Exp Med. 1984 Oct 01; 160(4):1126-46.
• Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, Krönke M, Svetlik PB, Peffer NJ, Waldmann TA. Nature. 1984 Oct 18-24; 311(5987):626-31.
• Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Krönke M, Leonard WJ, Depper JM, Arya SK, Wong-Staal F, Gallo RC, Waldmann TA, Greene WC. Proc Natl Acad Sci U S A. 1984 Aug; 81(16):5214-8.
• Phorbol diester induces expression of Tac antigen on human acute T lymphocytic leukemic cells. Greene WC, Robb RJ, Depper JM, Leonard WJ, Drogula C, Svetlik PB, Wong-Staal F, Gallo RC, Waldmann TA. J Immunol. 1984 Aug; 133(2):1042-7.
• Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. Waldmann TA, Greene WC, Sarin PS, Saxinger C, Blayney DW, Blattner WA, Goldman CK, Bongiovanni K, Sharrow S, Depper JM. J Clin Invest. 1984 Jun; 73(6):1711-8.
• Expression of receptors for interleukin 2: Role in the commitment of T lymphocytes to proliferate. Lipkowitz S, Greene WC, Rubin AL, Novogrodsky A, Stenzel KH. J Immunol. 1984 Jan; 132(1):31-7.
• In: Greaves M (Ed.), Receptors and Recognition Leonard WJ, Depper JM, Waldmann TA, Greene WC. . A monoclonal antibody to the human receptor for T cell growth factor. 1984; 17:45-66.
• In: Pick E (Ed.), Lymphokines Depper JM, Leonard WJ, Waldmann TA, Greene WC. . A monoclonal antibody which recognizes the human receptor for T cell growth factor: Functional effects and use as a probe to investigate receptor regulation. 1984; 9:127-152.
• In: Sasazuki T (Ed.), Immunogenetics: Its application to clinical medicine Waldmann TA, Broder S, Greene WC. . Cell-cell interactions in the human immune response: Analysis of leukemic T calls with immunoregulatory functions. 1984; 137-142.
• Interleukin-2 receptor expression in retrovirus associated adult T-cell leukemia. Waldmann TA, Leonard WJ, Depper JM, Krönke M, Goldman CK, Oh T, Greene WC. Princess Takamatsu Symp. 1984; 15:259-68.
• Interleukin-2 receptors on activated malignant and normal B-cells. Waldmann TA, Goldman CK, Leonard WJ, Depper JM, Robb RJ, Korsmeyer SJ, Greene WC. Curr Top Microbiol Immunol. 1984; 113:96-101.
• Monoclonal lupus autoantibody secretion by human-human hybridomas. Selection of hybrids by conventional and novel techniques. Littman BH, Muchmore AV, Steinberg AD, Greene WC. J Clin Invest. 1983 Dec; 72(6):1987-94.
• Characterization of the human receptor for T-cell growth factor. Leonard WJ, Depper JM, Robb RJ, Waldmann TA, Greene WC. Proc Natl Acad Sci U S A. 1983 Nov; 80(22):6957-61.
• Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. Lando Z, Sarin P, Megson M, Greene WC, Waldman TA, Gallo RC, Broder S. Nature. 1983 Oct 20-26; 305(5936):733-6.
• Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen. Robb RJ, Greene WC. J Exp Med. 1983 Oct 01; 158(4):1332-7.
• Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. J Immunol. 1983 Aug; 131(2):690-6.
• Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Korsmeyer SJ, Greene WC, Cossman J, Hsu SM, Jensen JP, Neckers LM, Marshall SL, Bakhshi A, Depper JM, Leonard WJ, Jaffe ES, Waldmann TA. Proc Natl Acad Sci U S A. 1983 Jul; 80(14):4522-6.
• Evidence for an interleukin-independent pathway for human lymphocyte activation. Koretzky GA, Daniele RP, Greene WC, Nowell PC. Proc Natl Acad Sci U S A. 1983 Jun; 80(11):3444-7.
• Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen. Cossman J, Neckers LM, Leonard WJ, Greene WC. J Exp Med. 1983 Mar 01; 157(3):1064-9.
• Construction of human suppressor T cell hybridomas. Greene WC, Depper JM, Leonard WJ, Fleisher TA, Waldmann TA. Lymphokine Res. 1983; 2(2):53-60.
• In: Golde DW, Marks PA (Eds.), Normal and Neoplastic Hematopoiesis, UCLA Symposia on Molecular and Cellular Biology Greene WC, Cossman J, Leonard WJ, Bakshi A, Waldmann TA, Korsmeyer SJ. . Hairy cell leukemia: A malignant expansion of B cells that express Tac antigen. 1983; 9:491-500.
• The role of cell surface lectin--carbohydrate interactions in cellular recognition, cooperation, and regulation. Blaese RM, Tosato G, Greene WC, Fleisher TA, Muchmore AV. Am J Pediatr Hematol Oncol. 1983; 5(2):199-206.
• A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC. Nature. 1982 Nov 18; 300(5889):267-9.
• Production of human suppressor T cell hybridomas. Greene WC, Fleisher TA, Nelson DL, Waldmann TA. J Immunol. 1982 Nov; 129(5):1986-92.
• Characterization of a soluble suppressor of human B cell function produced by a continuous human suppressor T cell line. II. Evidence for suppression through a direct action of CTC-SISS-B on human B cells. Greene WC, Fleisher TA, Depper JM, Leonard WJ, Stanton GJ, Waldmann TA. J Immunol. 1982 Sep; 129(3):1120-3.
• Interferon-mediated inhibition of human polyclonal immunoglobulin synthesis. Fleisher TA, Attallah AM, Tosato G, Blaese RM, Greene WC. J Immunol. 1982 Sep; 129(3):1099-103.
• In: Oppenheim JJ, Cohen S (Eds.), Interleukins, lymphokines, and cytokines Depper JM, Leonard WJ, Smith KA, Waldmann TA, Greene WC. . Monoclonal anti-Tac blocks the action of human interleukin-2. 1982; 19-24.
• Stimulation of immunoglobulin biosynthesis in human B cells by wheat germ agglutinin. I. Evidence that WGA can produce both a positive and negative signal for activation of human lymphocytes. Greene WC, Goldman CK, Marshall ST, Fleisher TA, Waldmann TA. J Immunol. 1981 Aug; 127(2):799-804.
• Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line. Fleisher TA, Greene WC, Uchiyama T, Goldman CK, Nelson DL, Blaese RM, Waldmann TA. J Exp Med. 1981 Jul 01; 154(1):156-67.
• Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. I. Characterization of a soluble suppressor T cell proliferation. Greene WC, Fleisher TA, Waldmann TA. J Immunol. 1981 Mar; 126(3):1185-91.
• Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. II. Characterization of a soluble suppressor of B cell immunoglobulin production. Fleisher TA, Greene WC, Blaese RM, Waldmann TA. J Immunol. 1981 Mar; 126(3):1192-7.
• Suppression of human T and B lymphocyte activation by Agaricus bisporus lectin. I. Suggestive evidence for a surface "suppressor" receptor in human lymphocytes. Greene WC, Fleisher TA, Waldmann TA. J Immunol. 1981 Feb; 126(2):580-6.
• Inhibition of human lymphocyte proliferation by the nonmitogenic lectin wheat germ agglutinin. Greene WC, Waldmann TA. J Immunol. 1980 Jun; 124(6):2979-87.
• In: Cramer H, Schultz J (Eds.), Mechanism of Action Parker CW, Greene WC. . Cyclic nucleotides in the immune response. 1977; 161-187.
• Cytochalasin binding in lymphocytes and polymorphonuclear leukocytes. Parker CW, Greene WC, MacDonald HH. Exp Cell Res. 1976 Nov; 103(1):99-108.
• Cytochalasin sensitive structures and lymphocyte activation. Greene WC, Parker CM, Parker CW. Exp Cell Res. 1976 Nov; 103(1):109-17.
• Colchicine-sensitive structures and lymphocyte activation. Greene WC, Parker CM, Parker CW. J Immunol. 1976 Sep; 117(3):1015-22.
• Opposing effects of mitogenic and nonmitogenic lectins on lymphocyte activation. Evidence that wheat germ agglutinin produces a negative signal. Greene WC, Parker CM, Parker CW. J Biol Chem. 1976 Jul 10; 251(13):4017-25.
• Calcium and lymphocyte activation. Greene WC, Parker CM, Parker CW. Cell Immunol. 1976 Jul; 25(1):74-89.
• Studies on the stimulation of cAMP metabolism in human lymphocytes by latex polymers. Atkinson JP, Greene WC, McNearney TA, Parker CW. Exp Cell Res. 1976 May; 99(2):395-407.
• In: Eijsvoogel W, Roos D, Zeijlemaker WP (Eds.), Leukocyte membrane determinants regulating immune reactivity Greene WC, Wedner HJ, Parker CW. . Calcium ionophore A23187 and lymphocyte activation. 1976; 10:129.
• Suggestive evidence for both stimulatory and inhibitory domains on human lymphocytes, as indicated by phospholipid turnover studies with wheat germ agglutinin and other lectins. Parker CW, Dankner RE, Falkenhein SF, Greene WC. Immunol Commun. 1976; 5(1-2):13-25.
• A role for cytochalasin-sensitive proteins in the regulation of calcium transport in activated human lymphocytes. Greene WC, Parker CW. Biochem Biophys Res Commun. 1975 Jul 22; 65(2):456-63.
• Concanavalin A-induced histamine release from normal rat mast cells. Sullivan TJ, Greene WC, Parker CW. J Immunol. 1975 Jul; 115(1):278-82.
• Effect of experimental diabetes mellitus on kidney ribosomal protein synthesis. Peterson DT, Greene WC, Reaven GM. Diabetes. 1971 Oct; 20(10):649-54.

More Publications

Contact